NRD
CLDX icon

Nebula Research & Development’s Celldex Therapeutics CLDX Stock Holding History

Nebula Research & Development’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,169
Closed -$275K – 980
2025
Q1 		$275K Buy
15,169
+1,142
+8% +$25.5K 0.03% 784
2024
Q4 		$354K Buy
+14,027
New +$381K 0.04% 671

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's CLDX Position: Q2 2025 in Review

Nebula Research & Development sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 15,169 shares — an estimated $275K sold.

Nebula Research & Development first reported a position in CLDX in Q4 2024 and held it in 2 quarters. The position peaked at $354K in Q4 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Nebula Research & Development reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 15,169 Celldex Therapeutics shares in Q2 2025, an estimated $275K.
  • Nebula Research & Development first reported a position in Celldex Therapeutics in Q4 2024 and held it in 2 quarters.
  • Nebula Research & Development's Celldex Therapeutics position peaked at $354K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.